257 related articles for article (PubMed ID: 33250051)
1. KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer.
De Donato M; Babini G; Mozzetti S; Buttarelli M; Ciucci A; Arduini G; De Rosa MC; Scambia G; Gallo D
J Exp Clin Cancer Res; 2020 Nov; 39(1):265. PubMed ID: 33250051
[TBL] [Abstract][Full Text] [Related]
2. Krüppel-Like Factor 7 is a Marker of Aggressive Gastric Cancer and Poor Prognosis.
Jiang Z; Yu T; Fan Z; Yang H; Lin X
Cell Physiol Biochem; 2017; 43(3):1090-1099. PubMed ID: 28977783
[TBL] [Abstract][Full Text] [Related]
3. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
[TBL] [Abstract][Full Text] [Related]
4. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
5. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
[TBL] [Abstract][Full Text] [Related]
6. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer.
Coan M; Rampioni Vinciguerra GL; Cesaratto L; Gardenal E; Bianchet R; Dassi E; Vecchione A; Baldassarre G; Spizzo R; Nicoloso MS
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149579
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
Lu H; Cunnea P; Nixon K; Rinne N; Aboagye EO; Fotopoulou C
Br J Cancer; 2021 Mar; 124(7):1286-1293. PubMed ID: 33473167
[TBL] [Abstract][Full Text] [Related]
9. Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.
De Donato M; Petrillo M; Martinelli E; Filippetti F; Zannoni GF; Scambia G; Gallo D
Gynecol Oncol; 2017 Jul; 146(1):170-178. PubMed ID: 28495238
[TBL] [Abstract][Full Text] [Related]
10. High Expression of Krüppel-like Factor 7 Indicates Unfavorable Clinical Outcomes in Patients with Lung Adenocarcinoma.
Niu R; Tang Y; Xi Y; Jiang D
J Surg Res; 2020 Jun; 250():216-223. PubMed ID: 32092599
[TBL] [Abstract][Full Text] [Related]
11. NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells.
Liu C; Vorderbruggen M; Muñoz-Trujillo C; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS; Karpf AR
J Ovarian Res; 2024 May; 17(1):94. PubMed ID: 38704607
[TBL] [Abstract][Full Text] [Related]
12. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of intra-tumoral budding in high-grade serous ovarian carcinomas.
Hachisuga T; Murakami M; Harada H; Ueda T; Kurita T; Kagami S; Yoshino K; Tajiri R; Hisaoka M
Sci Rep; 2022 Feb; 12(1):3153. PubMed ID: 35210538
[TBL] [Abstract][Full Text] [Related]
14. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
Kenda Suster N; Smrkolj S; Virant-Klun I
J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
[TBL] [Abstract][Full Text] [Related]
15. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.
Drumond-Bock AL; Bieniasz M
Mol Cancer; 2021 Nov; 20(1):145. PubMed ID: 34758842
[TBL] [Abstract][Full Text] [Related]
16. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
[TBL] [Abstract][Full Text] [Related]
17. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
[TBL] [Abstract][Full Text] [Related]
18. Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer.
Lee SW; Lee HY; Kang SW; Kim MJ; Lee YJ; Sung CO; Kim YM
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502561
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
20. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]